このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Risk Factors and Early Predictors of Bile Leak After Major Liver Resection (BILE-PREDICT)

2026年11月12日 更新者:Saleh Khairy Saleh MD、Minia University

Risk Factors and Early Predictors of Bile Leak After Major Hepatectomy: A Prospective Observational Cohort Study

The goal of this observational study is to learn how often bile leaks after major liver surgery, which factors increase the risk of a leak, and whether simple bilirubin tests on the fluid collected by the surgical drain in the first days after the operation can predict a serious leak. The study will include adults having planned removal of three or more liver segments (major hepatectomy) for any reason at Minia University, Egypt.

The main questions it aims to answer are:

  • How many patients develop a clinically relevant bile leak (one that needs a drainage procedure, an endoscopic procedure or a second operation) within 90 days after major hepatectomy?
  • Which patient, liver and operation-related factors are linked to bile leak?
  • Can the bilirubin level in the drain fluid, and its ratio to the blood bilirubin level, measured on days 1 and 3 after surgery, show which patients will develop a clinically relevant bile leak?

Participants are adults whose liver operation has already been planned as part of their regular medical care. Taking part does not change their operation or treatment. Participants will:

  • Have their usual pre-operative tests, operative details and hospital course recorded.
  • Have bilirubin measured in a small sample of the fluid collected by the abdominal drain placed at the end of the operation, together with a routine blood test, on days 1, 3 and 5 after surgery and later while the drain remains in place.
  • Be seen daily in hospital and at clinic visits about 2 weeks, 6 weeks and 90 days after surgery.

The researchers expect that higher drain-fluid bilirubin and a higher drain-to-blood bilirubin ratio early after surgery will identify patients at risk of a clinically relevant leak. If so, these simple tests could help surgeons decide when a drain can be removed safely and when a patient needs early investigation.

調査の概要

状態

まだ募集していません

条件

介入・治療

詳細な説明

Background

Bile leak is one of the most frequent complications of liver resection and an important cause of morbidity after hepatectomy. In 2011 the International Study Group of Liver Surgery (ISGLS) defined post-hepatectomy bile leak as a bilirubin concentration in the drain fluid at least 3 times the simultaneous serum bilirubin concentration on or after postoperative day (POD) 3, or the need for radiological or operative intervention for biliary collections or bile peritonitis. Severity is graded by its effect on clinical management: grade A causes no change in management, grade B requires active therapeutic intervention without relaparotomy, and grade C requires relaparotomy (Koch et al., 2011).

Prospective ISGLS-graded series show a wide range of incidence. In an international multicenter study of 949 consecutive liver resections, bile leak occurred in 7.3% of patients (grade A 3.3%, grade B 3.4%, grade C 0.6%); severity correlated with the Clavien-Dindo classification, and median hospital stay increased from 7 to 15 days when a leak occurred (Brooke-Smith et al., 2015). In 501 consecutive resections the overall rate was 14.0% (grade B 8.0%, grade C 3.2%), and pre-operative chemotherapy, major hepatectomy and biliodigestive reconstruction were independent risk factors (Spetzler et al., 2019). In 265 elective resections, grade B and grade C leaks occurred in 14.3% and 4.1% of patients, with perioperative mortality of 5.2% and 45.4%, respectively (Rahbari et al., 2012).

Other reported risk factors include central hepatectomy, prolonged operative time and Child-Pugh class B cirrhosis (Nakano et al., 2018), and non-anatomical resection (Panaro et al., 2016; Kajiwara et al., 2016). A 2023 meta-analysis of 39 studies including 43,824 patients identified, among other factors, repeat hepatectomy, extended hepatectomy, diabetes, Child-Pugh class B or worse and chemotherapy as factors associated with grade B/C bile leak (Xue et al., 2023).

Early biochemical detection is attractive because it could allow safe early drain removal in low-risk patients and prompt investigation in those developing a clinically relevant leak. A drain-fluid bilirubin concentration of 2.4 mg/dL or more on POD 2 independently predicted grade B/C leak (odds ratio 11.88, 95% CI 5.33 to 26.49) (Rahbari et al., 2012). After complex hepatectomy, drain-fluid total bilirubin on POD 3 had the highest predictive value for grade B leak (Taguchi et al., 2014), and in 576 resections the drain-to-serum bilirubin ratio discriminated grade B/C leak with areas under the curve of 0.788 on POD 1, 0.791 on POD 2 and 0.650 on POD 3 (Sliwinski et al., 2023).

Rationale

Most published evidence is retrospective, heterogeneous in definitions, case mix and drainage policy, and drawn from mixed minor and major resections. Prospective data that apply the ISGLS definition uniformly to major hepatectomy, and that evaluate pre-operative, intraoperative and early biochemical predictors in the same cohort, remain limited. Drain-fluid bilirubin and the drain-to-serum bilirubin ratio are inexpensive and widely available, and could directly inform drain management and enhanced-recovery pathways. No prospective ISGLS-based analysis of bile leak after major hepatectomy has been reported from this institution.

Objectives

Primary objective: to estimate the incidence of clinically relevant (ISGLS grade B/C) bile leak within 90 days after major hepatectomy.

Secondary objectives:

  • To estimate the incidence of any (grade A/B/C) bile leak.
  • To identify pre-operative and intraoperative factors associated with bile leak by univariable and exploratory multivariable analysis.
  • To evaluate the diagnostic accuracy (area under the curve, sensitivity, specificity and optimal cut-off) of drain-fluid total bilirubin, drain-fluid direct bilirubin and the drain-to-serum bilirubin ratio on POD 1 and POD 3 for predicting clinically relevant bile leak.
  • To describe the management and clinical course of bile leak (interventions required and time to resolution) and its association with post-hepatectomy liver failure, overall morbidity (Clavien-Dindo grade and Comprehensive Complication Index), length of stay and 90-day mortality.

Hypotheses

Null hypothesis: early drain-fluid bilirubin and the drain-to-serum bilirubin ratio do not discriminate between patients who do and do not develop clinically relevant bile leak, and the candidate pre-operative and intraoperative factors are not associated with bile leak.

Alternative hypothesis: higher early drain-fluid bilirubin and a higher drain-to-serum bilirubin ratio are associated with, and predictive of, clinically relevant bile leak, and defined pre-operative and intraoperative factors are independently associated with its occurrence.

Design and Setting

Single-center, prospective, observational cohort study, conducted and reported in accordance with the STROBE statement (von Elm et al., 2007). The study takes place in the Hepato-Pancreato-Biliary (HPB) Unit, Department of General Surgery, Liver and Gastrointestinal Tract Hospital, Faculty of Medicine, Minia University, Minia, Egypt, and forms the thesis research for the Master of Science degree in General Surgery, Faculty of Medicine, Minia University.

Participants and Enrollment

Consecutive adults scheduled for elective major hepatectomy are screened and, after written informed consent, enrolled at the decision to operate (consecutive, total-population sampling). The eligibility criteria are listed in the Eligibility section of this record. Participants in whom no abdominal drain is placed (unless bile leak is diagnosed by intervention), and those who die within 72 hours of surgery from a cause unrelated to bile leak, are recorded as non-evaluable for the primary outcome and reported in the STROBE flow diagram.

Operational Definitions

  • Major hepatectomy: resection of 3 or more contiguous Couinaud segments.
  • Bile leak (ISGLS): drain-fluid bilirubin at least 3 times the simultaneous serum bilirubin on or after POD 3, or the need for radiological or operative intervention for biliary collection or bile peritonitis. Grade A: no change in management; grade B: active therapeutic intervention without relaparotomy; grade C: relaparotomy.
  • Clinically relevant bile leak: ISGLS grade B or C (primary outcome).
  • Post-hepatectomy liver failure (ISGLS): increased international normalized ratio (INR) with concomitant hyperbilirubinemia on or after POD 5, graded A to C (Rahbari et al., Surgery 2011).
  • Post-hepatectomy hemorrhage (ISGLS): defined and graded according to the ISGLS (Rahbari et al., HPB 2011).
  • Overall morbidity: graded by the Clavien-Dindo classification (Dindo et al., 2004) and summarized by the Comprehensive Complication Index (Slankamenac et al., 2013).
  • Drain-to-serum bilirubin ratio: drain-fluid total bilirubin divided by the simultaneous serum total bilirubin, calculated on POD 1 and POD 3.

Study Procedures

Pre-operative assessment: history and examination, routine hematology and biochemistry (including liver profile, INR and albumin), tumor markers as indicated, and triphasic computed tomography and/or magnetic resonance imaging with volumetric assessment of the future liver remnant when major resection is planned. Liver function is characterized by Child-Pugh class and, where available, indocyanine green retention at 15 minutes (ICG-R15). Baseline variables are recorded prospectively on the case report form.

Operation and drainage: resections are performed by the unit's HPB surgeons according to standard practice (open or minimally invasive), with parenchymal transection and hemostasis by the operator's usual technique. The biliary integrity of the cut surface is assessed according to unit practice, and use of an intraoperative bile-leak test is recorded. In line with the unit's drainage practice after major hepatectomy, a closed-suction abdominal drain is placed adjacent to the transection surface at the end of the procedure, including all cases with biliary reconstruction; the protocol standardizes drain position and the sampling schedule so that bile leak can be assessed uniformly. Operative details are recorded at the time of surgery.

Postoperative sampling and monitoring:

  • Drain-fluid total and direct bilirubin on POD 1 and POD 3, and on POD 5 and subsequently while the drain remains in place, each with a simultaneous serum total bilirubin to calculate the drain-to-serum ratio.
  • Daily drain output volume and character.
  • Serum liver profile, INR, C-reactive protein and white cell count at least on POD 1, 3 and 5, per unit protocol.
  • Drain removal, escalation of care and any radiological, endoscopic or surgical intervention, each with its indication.

Samples are analyzed in the hospital laboratory and are not stored. Drain removal and all management decisions remain with the treating team; no experimental intervention is imposed.

Outcome ascertainment and follow-up: participants are assessed daily during the index admission and reviewed in the outpatient clinic approximately 2 weeks, 6 weeks and 90 days after surgery, or more often if clinically indicated. Readmissions and interventions within 90 days are captured. Bile leak, post-hepatectomy liver failure and post-hepatectomy hemorrhage are graded according to the ISGLS definitions; the diagnosis and grade of bile leak are assigned prospectively by the managing team and independently verified by the investigators.

Candidate Predictors

  • Demographic and baseline: age, sex, body mass index, smoking, diabetes mellitus, American Society of Anesthesiologists (ASA) physical status, and nutritional risk (serum albumin, weight loss).
  • Hepatic and disease-related: underlying diagnosis; cirrhosis and Child-Pugh class; portal hypertension; pre-operative jaundice (obstructive or non-obstructive); ICG-R15 where available; serum bilirubin, albumin, INR, platelet count, transaminases and alkaline phosphatase; future liver remnant volume where measured.
  • Neoadjuvant and pre-operative: systemic chemotherapy; biliary drainage or intervention (endoscopic or percutaneous).
  • Operative: extent of resection (right, left, extended or central); anatomical or non-anatomical resection; biliary reconstruction (hepaticojejunostomy); hilar dissection or caudate involvement; operative time; estimated blood loss; intraoperative transfusion; Pringle maneuver and total clamp time; cut-surface area; intraoperative bile-leak test; concomitant procedures.
  • Early postoperative: drain-fluid total and direct bilirubin and the drain-to-serum total bilirubin ratio on POD 1 and POD 3; daily drain output volume; serum bilirubin trajectory; C-reactive protein and white cell count on POD 3.

Sample Size

The sample size is based on the primary descriptive objective, estimating a single proportion with adequate precision. The expected incidence of clinically relevant bile leak after major hepatectomy is 12%; in prospective ISGLS-graded series of all liver resections, grade B/C leak occurred in 4.0% to 18.4% of patients, and major hepatectomy was an independent risk factor (Brooke-Smith et al., 2015; Spetzler et al., 2019; Rahbari et al., 2012). With 95% confidence (Z = 1.96) and an absolute precision of plus or minus 8%, n = Z² × p(1 - p) / d² = (1.96² × 0.12 × 0.88) / 0.08² = 63.4, rounded up to 64 evaluable patients. Allowing about 10% non-evaluable patients (early unrelated death, absent drain or loss to follow-up), at least 72 patients are required.

To strengthen the risk-factor and diagnostic-accuracy objectives, all consecutive eligible patients presenting during the 18-month recruitment period will be enrolled, with a target of at least 90 evaluable patients (about 100 enrolled). With 90 evaluable patients, the 95% confidence interval for an incidence of 12% has a half-width of about plus or minus 6.7%. At the anticipated incidence, 90 patients yield roughly 10 to 12 grade B/C events, a low number of events per variable (Peduzzi et al., 1996); multivariable modeling is therefore pre-specified as exploratory. Where feasibility permits, recruitment may be extended to accrue additional events, and this record will be updated accordingly.

Statistical Analysis

Analyses will use SPSS or R, with two-sided tests and a significance level of 0.05.

  • Descriptive statistics: continuous variables as mean (SD) or median (IQR) according to distribution (Shapiro-Wilk test); categorical variables as frequencies and percentages. The incidence of bile leak, overall and by grade, is reported with 95% confidence intervals.
  • Univariable comparisons: patients with and without bile leak are compared with the independent-samples t test or Mann-Whitney U test for continuous variables, and the chi-square or Fisher exact test for categorical variables.
  • Exploratory multivariable analysis: variables with P < 0.10 on univariable analysis, together with clinically important predictors, are entered into a Firth penalized-likelihood logistic regression model, with the number of covariates limited by the number of events. Adjusted odds ratios with 95% confidence intervals are reported; discrimination is assessed by the area under the curve and calibration by the Hosmer-Lemeshow test.
  • Diagnostic accuracy of early predictors: receiver operating characteristic (ROC) analysis quantifies the area under the curve (AUC) of drain-fluid total bilirubin, drain-fluid direct bilirubin and the drain-to-serum bilirubin ratio on POD 1 and POD 3 for clinically relevant (grade B/C) bile leak. Optimal cut-offs are identified by the Youden index and reported with sensitivity, specificity and predictive values; AUCs on POD 1 and POD 3 are compared by the DeLong method.
  • Because grade B/C events are expected to be few, the AUCs of the POD 1 parameters are also evaluated against bile leak of any grade. POD 3 values are not evaluated against any-grade leak, because the ISGLS biochemical criterion is applied from POD 3 and its use would bias the estimates (incorporation bias).
  • Missing data: the extent and pattern of missing data are reported; complete-case analysis is used with a sensitivity analysis, and multiple imputation is considered if data are plausibly missing at random.
  • Pre-specified subgroup descriptions, by extent of resection and by biliary reconstruction, are reported where numbers permit.

Data Management and Quality Control

Data are recorded prospectively on a standardized case report form, pseudonymized with a study identification number, and entered into a secured, access-controlled electronic database with range and consistency checks at entry. The case report form is piloted and finalized before enrollment begins. Source documents are retained according to institutional policy to permit verification, and only the investigators have access to the data.

Ethical Considerations

The protocol was approved by the Medical Research Ethics Committee (Institutional Review Board), Faculty of Medicine, Minia University (MUFMIRB approval number 2259:11/26, 4 November 2026), which operates according to the Declaration of Helsinki, CIOMS and ICH-GCP guidelines and Egyptian Law No. 214 of 2020. The study is conducted in accordance with the Declaration of Helsinki (2013 revision). Written informed consent is obtained from every participant; participation is voluntary, and refusal does not affect the standard of care. The study observes routine surgical care: the standardized drain position and drain-fluid sampling add minimal incremental risk, and treatment decisions remain with the treating team. Serious adverse events are reported immediately to the committee chair, protocol changes are implemented only after committee approval, an annual report is submitted (the approval is valid for one year and will be renewed), and an end-of-study notification is filed.

Timeline

Ethical approval was granted on 4 November 2026, and the study is registered before enrollment begins. Prospective enrollment runs for 18 months, from 25 November 2026 to 24 May 2028; 90-day follow-up is completed by August 2028, followed by analysis and thesis write-up and submission by October 2028.

Reporting and Dissemination

Results will be reported according to the STROBE statement, presented as an MSc thesis and submitted for publication in a peer-reviewed journal.

Limitations

The single-center design may limit generalizability; the expected number of events constrains multivariable modeling, which is exploratory and hypothesis-generating; routine drainage differs from selective or no-drain policies; and case mix (indication, extent of resection and biliary reconstruction) is heterogeneous.

研究の種類

観察的

入学 (推定)

100

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Minia Governorate
      • Minya、Minia Governorate、エジプト
        • Liver and GIT Hospital, Faculty of Medicine, Minia University
        • コンタクト:
        • 主任研究者:
          • Saleh Khairy Saleh, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Consecutive adults scheduled for elective major hepatectomy (resection of 3 or more contiguous Couinaud segments) for malignant or benign liver disease at the Hepato-Pancreato-Biliary Unit, Liver and Gastrointestinal Tract Hospital, Faculty of Medicine, Minia University, Minia, Egypt, during an 18-month recruitment period.

説明

Inclusion Criteria:

  • Age 18 years or older.
  • Scheduled for elective major hepatectomy, defined as resection of three or more contiguous Couinaud segments (for example right or left hepatectomy, right or left trisectionectomy, or extended or central major resection), by an open or minimally invasive approach.
  • Any underlying indication, including hepatocellular carcinoma, colorectal or non-colorectal liver metastases, cholangiocarcinoma, other primary liver tumors, or benign disease.
  • Written informed consent.

Exclusion Criteria:

  • Minor resection (fewer than three contiguous segments) or non-anatomical wedge resection only.
  • Emergency hepatectomy (for example for trauma or spontaneous tumor rupture).
  • Liver transplantation or living-donor hepatectomy.
  • Two-stage hepatectomy or associating liver partition and portal vein ligation for staged hepatectomy (ALPPS).
  • Simultaneous major resection of another organ that itself involves a biliary or enteric anastomosis confounding drain-fluid biochemistry (for example pancreatoduodenectomy).
  • No intraoperative abdominal drain placed, unless bile leak is diagnosed by radiological or operative intervention (assessed at surgery; participant recorded as non-evaluable).
  • Death within 72 hours of surgery from a cause unrelated to bile leak (participant recorded as non-evaluable).
  • Refusal of consent or inability to complete 90-day follow-up.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Major hepatectomy cohort

Consecutive adults (18 years or older) undergoing elective major hepatectomy (resection of 3 or more contiguous Couinaud segments) for any malignant or benign indication at the HPB Unit, Liver and Gastrointestinal Tract Hospital, Minia University. All participants receive standard peri-operative care. A closed-suction drain is placed adjacent to the transection surface at the end of surgery according to unit practice, and drain-fluid total and direct bilirubin, with simultaneous serum bilirubin, are measured on postoperative days 1, 3 and 5 and thereafter while the drain remains. Participants are followed for 90 days. The investigators do not assign or modify treatment.

Elective resection of 3 or more contiguous Couinaud segments (right or left hepatectomy, right or left trisectionectomy, or extended or central major resection), open or minimally invasive, with or without biliary reconstruction, performed by the unit's HPB surgeons according to standard practice and ending with placement of a closed-suction drain adjacent to the transection surface. The operation is clinically indicated and planned before enrollment; the study does not assign or modify it.

他の名前:
  • Major liver resection
  • Hemihepatectomy
  • Trisectionectomy

Total and direct (conjugated) bilirubin measured in fluid from the closed-suction abdominal drain on postoperative days 1 and 3, and on day 5 and subsequently while the drain remains, each with a simultaneous serum total bilirubin to calculate the drain-to-serum bilirubin ratio. Fluid is taken from the drain collection without any additional procedure, analyzed in the hospital laboratory and not stored. Drain management remains at the discretion of the treating team.

他の名前:
  • Drain bilirubin
  • Drain-to-serum bilirubin ratio
  • Bilirubin ratio

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Clinically Relevant (ISGLS Grade B or C) Bile Leak
時間枠:From surgery to 90 days after surgery

Number and percentage of participants who develop bile leak of International Study Group of Liver Surgery (ISGLS) grade B or C, reported with a 95% confidence interval. Bile leak is defined as a drain-fluid bilirubin concentration at least 3 times the simultaneous serum bilirubin concentration on or after postoperative day 3, or the need for radiological or operative intervention for biliary collection or bile peritonitis. Grade B requires active therapeutic intervention (for example percutaneous drainage or endoscopic retrograde cholangiopancreatography with or without stenting) without relaparotomy; grade C requires relaparotomy. Diagnosis and grade are assigned prospectively by the treating team and independently verified by the investigators against the ISGLS criteria.

From surgery to 90 days after surgery

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of Any ISGLS Bile Leak (Grade A, B or C)
時間枠:From surgery to 90 days after surgery

Number and percentage of participants who meet the ISGLS definition of bile leak of any grade, reported with a 95% confidence interval. Grade A causes no change in clinical management; grades B and C are defined as for the primary outcome.

From surgery to 90 days after surgery
Severity Grade of Bile Leak (ISGLS Grade A, B and C)
時間枠:From surgery to 90 days after surgery

Number and percentage of participants with ISGLS grade A, grade B and grade C bile leak, respectively, reported among all evaluable participants and among those with bile leak.

From surgery to 90 days after surgery
Time From Surgery to Diagnosis of Bile Leak
時間枠:From surgery to 90 days after surgery

Postoperative day on which bile leak is first diagnosed according to the ISGLS definition (first drain-to-serum bilirubin ratio of 3 or more on or after postoperative day 3, or date of the first intervention for biliary collection or bile peritonitis), reported as median and interquartile range among participants with bile leak.

From surgery to 90 days after surgery
Pre-operative and Intraoperative Factors Associated With Bile Leak
時間枠:Pre-operative and intraoperative data; bile leak assessed from surgery to 90 days after surgery

Odds ratios with 95% confidence intervals for the association of each pre-specified candidate factor with bile leak of any grade and with clinically relevant (grade B/C) bile leak, from univariable analysis and an exploratory Firth penalized multivariable logistic regression model in which the number of covariates is limited by the number of events. Candidate factors: demographic and baseline (age, sex, body mass index, smoking, diabetes, ASA class, albumin, weight loss); hepatic and disease-related (diagnosis, cirrhosis and Child-Pugh class, portal hypertension, pre-operative jaundice, ICG-R15, liver tests, platelet count, future liver remnant volume); pre-operative chemotherapy and biliary drainage; operative (extent and type of resection, biliary reconstruction, hilar dissection or caudate involvement, operative time, blood loss, transfusion, Pringle maneuver and clamp time, cut-surface area, bile-leak test, concomitant procedures).

Pre-operative and intraoperative data; bile leak assessed from surgery to 90 days after surgery
Accuracy of Drain-Fluid Total Bilirubin on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak
時間枠:Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery

Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-fluid total bilirubin concentration (mg/dL) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.

Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery
Accuracy of Drain-Fluid Direct Bilirubin on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak
時間枠:Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery

Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-fluid direct (conjugated) bilirubin concentration (mg/dL) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.

Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery
Accuracy of the Drain-to-Serum Bilirubin Ratio on Postoperative Days 1 and 3 for Predicting Clinically Relevant Bile Leak
時間枠:Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery

Area under the receiver operating characteristic curve (AUC) with 95% confidence interval of the drain-to-serum total bilirubin ratio (drain-fluid total bilirubin divided by simultaneous serum total bilirubin) measured on postoperative day 1 and on postoperative day 3 for predicting ISGLS grade B or C bile leak. For each day, the optimal cut-off (maximum Youden index) is reported with its sensitivity, specificity and positive and negative predictive values. The AUCs on days 1 and 3 are compared by the DeLong method.

Measured on postoperative days 1 and 3; bile leak assessed to 90 days after surgery
Accuracy of Postoperative Day 1 Drain-Fluid Total Bilirubin for Predicting Bile Leak of Any Grade
時間枠:Measured on postoperative day 1; bile leak assessed to 90 days after surgery

AUC with 95% confidence interval of the drain-fluid total bilirubin concentration (mg/dL) on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).

Measured on postoperative day 1; bile leak assessed to 90 days after surgery
Accuracy of Postoperative Day 1 Drain-Fluid Direct Bilirubin for Predicting Bile Leak of Any Grade
時間枠:Measured on postoperative day 1; bile leak assessed to 90 days after surgery

AUC with 95% confidence interval of the drain-fluid direct (conjugated) bilirubin concentration (mg/dL) on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).

Measured on postoperative day 1; bile leak assessed to 90 days after surgery
Accuracy of the Postoperative Day 1 Drain-to-Serum Bilirubin Ratio for Predicting Bile Leak of Any Grade
時間枠:Measured on postoperative day 1; bile leak assessed to 90 days after surgery

AUC with 95% confidence interval of the drain-to-serum total bilirubin ratio on postoperative day 1 for predicting ISGLS bile leak of any grade (A, B or C), with the optimal cut-off (maximum Youden index) and its sensitivity, specificity and positive and negative predictive values. Day 3 values are not evaluated against any-grade leak because the ISGLS biochemical criterion is applied from postoperative day 3 (incorporation bias).

Measured on postoperative day 1; bile leak assessed to 90 days after surgery
Discrimination and Calibration of the Exploratory Multivariable Model for Bile Leak
時間枠:Bile leak assessed from surgery to 90 days after surgery

Apparent discrimination (AUC with 95% confidence interval) and calibration (Hosmer-Lemeshow goodness-of-fit test) of the exploratory Firth penalized logistic regression model of pre-operative and intraoperative factors for bile leak.

Bile leak assessed from surgery to 90 days after surgery
Management of Bile Leak
時間枠:From diagnosis of bile leak to 90 days after surgery

Number and percentage of participants with bile leak managed by each of the following (more than one may apply): observation with the drain kept in place; new or prolonged percutaneous drainage; endoscopic retrograde cholangiopancreatography with or without stenting; antibiotic therapy; and relaparotomy.

From diagnosis of bile leak to 90 days after surgery
Time to Resolution of Bile Leak
時間枠:From diagnosis of bile leak to 90 days after surgery

Days from diagnosis of bile leak to resolution, defined as cessation of bilious drainage with removal of all abdominal drains and no further biliary intervention, as documented by the treating team; reported as median and interquartile range.

From diagnosis of bile leak to 90 days after surgery
Incidence and Grade of Post-hepatectomy Liver Failure (ISGLS)
時間枠:From postoperative day 5 to 90 days after surgery

Number and percentage of participants with post-hepatectomy liver failure, defined by the ISGLS as an increased international normalized ratio with concomitant hyperbilirubinemia (local laboratory limits) on or after postoperative day 5, and graded A (no change in clinical management), B (deviation from the regular course without invasive treatment) or C (invasive treatment required); compared between participants with and without bile leak.

From postoperative day 5 to 90 days after surgery
Incidence and Grade of Post-hepatectomy Hemorrhage (ISGLS)
時間枠:From surgery to 90 days after surgery

Number and percentage of participants with post-hepatectomy hemorrhage, defined by the ISGLS as a fall in hemoglobin of more than 3 g/dL from the postoperative baseline, and/or postoperative red cell transfusion for falling hemoglobin, and/or radiological intervention or relaparotomy to stop bleeding; graded A (transfusion of up to 2 units), B (more than 2 units) or C (invasive reintervention).

From surgery to 90 days after surgery
Overall Postoperative Morbidity by Clavien-Dindo Grade
時間枠:From surgery to 90 days after surgery

Number and percentage of participants with any complication and with major complications (grade III or higher), classified by the highest Clavien-Dindo grade (I to V); compared between participants with and without bile leak.

From surgery to 90 days after surgery
Comprehensive Complication Index (CCI)
時間枠:From surgery to 90 days after surgery

Comprehensive Complication Index score (scale 0 to 100; 0 = no complication, 100 = death), calculated from all complications graded by the Clavien-Dindo classification; reported as median and interquartile range and compared between participants with and without bile leak.

From surgery to 90 days after surgery
Reintervention
時間枠:From surgery to 90 days after surgery

Number and percentage of participants requiring radiological, endoscopic or surgical reintervention for any cause, reported overall and by type.

From surgery to 90 days after surgery
Length of Postoperative Hospital Stay
時間枠:From surgery to discharge from the index admission (up to 90 days)

Days from surgery to discharge from the index admission; reported as median and interquartile range and compared between participants with and without bile leak.

From surgery to discharge from the index admission (up to 90 days)
Length of Intensive Care Unit Stay
時間枠:From surgery to discharge from the index admission (up to 90 days)

Number of days spent in the intensive care unit during the index admission; reported as median and interquartile range and compared between participants with and without bile leak.

From surgery to discharge from the index admission (up to 90 days)
Hospital Readmission
時間枠:From discharge to 90 days after surgery

Number and percentage of participants readmitted to hospital for any cause, and for bile leak-related causes, after discharge from the index admission.

From discharge to 90 days after surgery
All-Cause Mortality
時間枠:30 days and 90 days after surgery

Number and percentage of participants who die from any cause within 30 days and within 90 days after surgery; compared between participants with and without bile leak.

30 days and 90 days after surgery

その他の成果指標

結果測定
メジャーの説明
時間枠
Duration of Abdominal Drainage
時間枠:From surgery to removal of the last drain (up to 90 days)

Days from surgery to removal of the last abdominal drain; reported as median and interquartile range and compared between participants with and without bile leak.

From surgery to removal of the last drain (up to 90 days)
Incidence of Bile Leak by Type of Resection and Biliary Reconstruction
時間枠:From surgery to 90 days after surgery

Number and percentage of participants with bile leak of any grade and with clinically relevant (grade B or C) bile leak, by extent of resection (right, left, extended or central) and by presence or absence of biliary reconstruction; descriptive only.

From surgery to 90 days after surgery
Early Postoperative Variables Associated With Clinically Relevant Bile Leak
時間枠:Postoperative days 1 to 5; bile leak assessed to 90 days after surgery

Comparison of daily drain output volume (postoperative days 1 to 3), serum bilirubin trajectory (postoperative days 1, 3 and 5), and C-reactive protein and white cell count on postoperative day 3 between participants with and without clinically relevant bile leak, reported as median (IQR) or mean (SD) with univariable P values.

Postoperative days 1 to 5; bile leak assessed to 90 days after surgery

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Saleh Khairy Saleh, MD、Minia University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月25日

一次修了 (推定)

2028年8月31日

研究の完了 (推定)

2028年8月31日

試験登録日

最初に提出

2026年11月12日

QC基準を満たした最初の提出物

2026年11月12日

最初の投稿 (実際)

2026年11月19日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月19日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 2259:11/26

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。